Posts tagged infectious disease
Stifel ups Tetraphase to buy

Stifel upgraded Tetraphase Pharmaceuticals (NASDAQ:TTPH) to “buy” from “hold” and raised its price target to $15 from $8 after the company reported positive top-line results of the IGNITE4 clinical trial evaluating its eravacycline in patients with complicated intra-abdominal infections (cIAI). The stock closed at $6.90 on July 25.

Read More
Avivagen undertakes human health proof of concept

Avivagen (TSX-V:VIV), with the help of the National Research Council of Canada (NRC), will undertake a project to establish proof of concept for a first human health application of its OxC-beta technology.

Read More